Gilead Sciences, Inc. (NASDAQ:GILD) is among the Renaissance Technologies Portfolio: 10 Biggest Stocks. On September 16, JPMorgan analyst Chris Schott lifted the stock’s price target to $145 from $135 while maintaining an Overweight rating for its shares. JPMorgan Lifts Gilead Sciences, Inc. (GILD)'s Price Target To $145, Maintains Overweight Rating While the firm left most of its large-cap biopharma estimates unchanged, it adjusted share price targets on a move from December 2025 to December 2026. The ...

- Industry veteran brings over 35 years of biotech experience as a successful entrepreneur and investor - Operating experience to significantly enhance development program of CID-103 (anti-CD38 mAb) SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 26, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced the appointment of James Huang as ...

Woburn, MA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 1:15 p.m. ET on Tuesday, ...

Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for AmnealBRIDGEWATER, N.J., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a proposed biosimilar to XOLAIR® (omalizumab), developed by Kashiv BioSciences, LLC. XOLAIR® is a registered trademark of Novartis AG. Omalizumab, a humanized ...

Shares of Top KingWin Ltd (NASDAQ: WAI) rose sharply in pre-market trading after the company announced it entered into a sales contract with Walker Times International for the sale of 10,000 units of TK-D2C AI Robots.Top KingWin shares jumped 87.4% to $5.92 in the pre-market trading session.Here are some other stocks moving in pre-market trading.GainersMEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) rose 242% to $4.96 in pre-market trading. Medirom announced plans to double installation of Authentication ...

Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025 and host a conference call to discuss the results on October 1, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business upd ...

公司业务与研发进展 - 公司专注于开发罕见皮肤病治疗药物 是一家临床阶段生物制药公司[1] - 扩展QTORIN™ 3.9%雷帕霉素无水凝胶项目 新增临床显著性血管角化瘤适应症 该罕见淋巴疾病在美国影响超过50,000名患者[1] - 计划在2026年下半年启动II期临床试验 目标成为首个FDA批准的血管角化瘤疗法[1][2] - 当前治疗方案有限且通常伴随疼痛性操作 存在瘢痕形成和复发风险[2] - 计划2026年初与FDA会晤讨论II期研究设计 试验规模为10-20名患者[3] - 正在其他研究中评估QTORIN雷帕霉素 预计2025年12月中旬和2026年初获得结果[3] 技术平台与战略定位 - 持续利用专利保护的QTORIN平台开发新型疗法[3] - 公司战略聚焦于治疗严重罕见皮肤病的未满足医疗需求[2] 财务表现与流动性状况 - 当前市盈率为负值 -26.45 企业价值与经营现金流比率为负值 -42.71[5][6] - 流动比率达7.67 显示公司拥有充足流动资产覆盖负债[5][6] 市场评级与股价表现 - H.C. Wainwright于2025年9月25日将评级上调至"买入" 目标价从75美元提高至95美元[4] - Stifel Nicolaus分析师Annabel Samimy设定80美元目标价 较当时59.87美元价格存在约33.62%上涨潜力[4] - 评级调整时股价为58.87美元[4]

Accessibility StatementSkip Navigation PHILADELPHIA, Sept. 25, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Altimmune, Inc. (NASDAQ: ALT) ("Altimmune" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for obesity and liver disease, including MASH (metabolic dysfunction-associated steatohepatitis) after a class action lawsuit was filed against Altimmune. Investor Deadline: Investors who purchased ...

– KOMET-001 in R/R NPM1-m AML met its primary endpoint with ziftomenib monotherapy demonstrating significant clinical benefit and deep responses – – Consistent activity across pre-specified subgroups, regardless of prior HSCT, prior venetoclax, lines of therapy, or FLT3/IDH co-mutations – – Favorable safety and tolerability profile, including a lack of clinically significant QTc prolongation or myelosuppression – – Prescription Drug User Fee Act (PDUFA) target action date for FDA Priority Review of ziftomen ...

VANCOUVER, British Columbia and BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its early-stage programs targeting Kv7 and Nav1.7 as potential non-opioid treatments for pain. Webinar:Developing Novel Non-Opioid Treatments for ...